But several people with type 2 diabetes here in the metro are struggling to find the injectable for their medical needs
GLP-1/GCG Dual-Target MASH Drug Achieves Success in Phase II Trial June 16, 2025 D&D Pharmatech, a clinical-stage biotech company focused on breakthrough therapies for liver and metabolic diseases, announced that its Phase II DD01-DN-02 trial evaluating DD01 a long-acting dual GLP-1R/GCGR agonist in patients with metabolic dysfunction-associated steatohepatitis (MASH) who are overweight or obese has met its primary endpoint
Immunohistochemical analysis further substantiated these results, demonstrating decreased expressions of GLUT1, GLUT6, and Ki-67, accompanied by increased SREBP2 expression
Potential Cardiovascular Benefits: Some studies suggest benefits relating to heart health, a crucial consideration for those with diabetes
If you are the spouse or partner of someone on a GLP-1, it can be difficult to come up with meal ideas and prepare food that fits his or her needs and keeps side effects at bay
GLP-1/GIP/glucagon (triple G) receptor agonists 3.6.1
